The heat is on. It looks like the FDA is receiving heavy lobbying on both sides, so it has postponed, until mid-December, its decision on revoking the approval for Avastin® as treatment for breast cancer. Briefly, if the FDA revokes its approval for Avastin as a breast-cancer treatment, Avastin would remain only as an off-label treatment (it remains an approved treatment for brain, colon, kidney and lung cancers) and thus may not receive support from insurance carriers.
F.D.A. Postpones Rule on Breast Cancer Drug. By Andrew Pollack, The New York Times 9-17-10
5 6 7 8
© 2004-2010 Donna Peach. All rights reserved.